6-K ·Filed Jun 24, 2026

TAK

TAKEDA PHARMACEUTICAL CO LTD
NEUTRAL
Impact 3/10
Horizonmonths Processed3mo ago SEC0001395064-26-000183
Notable filing: 6-K
Actionable Insight • Neutral

Monitor Takeda's next quarterly earnings for any strategic shifts under the new CEO, particularly around the three major launches mentioned in forward-looking commentary. The CEO transition was well-telegraphed over 18 months, so no immediate stock reaction is expected.

DirectionNeutral
Confidencehigh
Horizonmonths
Final — all horizons settled through T+60d ⚠ clustered
TAK ▲ +21.18% at T+60d
NEUTRAL call ✓ call won +21.18% · α vs SPY +18.35% · entry $15.72 → $19.05
Entry anchored
Jun 23, 03:59 PM ET
via exchange tick
T+1d
-0.45%
call -0.45% · α -0.59%
$15.65
settled 3mo ago
T+5d
+1.46%
call +1.46% · α -0.24%
$15.95
settled 3mo ago
T+20d
+7.32%
call +7.32% · α +5.38%
$16.87
settled 2mo ago
T+60d
+21.18%
call +21.18% · α +18.35%
$19.05
settled 14d ago

Price Chart

Loading chart...

Executive Summary

Takeda announced the official appointment of Julie Kim as Representative Director, President & CEO, completing an 18-month CEO transition. Former CEO Christophe Weber retired, and three new external directors were elected to the Board. The filing is a routine leadership succession announcement with no financial data or material operational changes reported.

Key Facts

  • Julie Kim appointed Representative Director, President & CEO effective June 24, 2026
  • Former CEO Christophe Weber retired after 12 years
  • Three new external directors elected: Bruce Broussard, Koichiro Kimura, Dr. Paul Stoffels
  • Board now has 8 external directors out of 11 total members
  • Audit, Nomination, and Compensation Committees composed solely of external directors
  • No financial figures, guidance, or material operational changes reported

Financial Impact

No financial impact reported in this filing

Risk Factors

  • Execution risk on pipeline launches under new leadership
  • Potential strategic pivot under new CEO not yet quantifiable

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
68% bullish (19 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001395064-26-000183
Document: form6k-2_062426.htm0001395064-26-000183
Document: 0001395064-26-000183-index-headers.html0001395064-26-000183
Document: 0001395064-26-000183-index.html0001395064-26-000183
Document: 0001395064-26-000183.txt0001395064-26-000183
13 reports for TAK
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for TAK — sortable, filterable
TypeNow
Sep 14, 2026
18d ago
6-K
BULLISH ★ 7/10
$18.60 $18.89▲ +1.56%▲ +1.45%$17.86 (−3.98%)
Aug 21, 2026
6w ago
Insider Cluster
NEUTRAL ★ 2/10
$18.18 $18.03▼ −0.83%▼ −1.30%$17.86 (−1.76%)
Aug 19, 2026
6w ago
Insider Cluster
NEUTRAL ★ 2/10
$18.34 $18.23▼ −0.60%▼ −0.21%$17.86 (−2.62%)
Aug 14, 2026
7w ago
Court Ruling
NEUTRAL ★ 4/10
$17.63 $18.18▲ +3.12%▲ +4.49%$17.86 (+1.30%)
Aug 13, 2026
7w ago
Insider Cluster
NEUTRAL ★ 3/10
$17.39 $18.13▲ +4.26%▲ +6.22%$17.86 (+2.70%)
Aug 13, 2026
7w ago
Insider Cluster
NEUTRAL ★ 2/10
$17.39 $18.13▲ +4.26%▲ +6.22%$17.86 (+2.70%)
Jul 9, 2026
12w ago
6-K
NEUTRAL ★ 2/10
$16.61 $16.73▲ +0.72%▲ +0.85%$17.86 (+7.53%)
Jul 8, 2026
12w ago
6-K
NEUTRAL ★ 2/10
$16.75 $16.39▼ −2.15%▼ −3.01%$17.86 (+6.63%)
Jul 6, 2026
12w ago
3
NEUTRAL ★ 2/10
$16.89 $16.56▼ −1.95%▼ −2.44%$17.86 (+5.74%)
Jun 29, 2026
13w ago
6-K
NEUTRAL ★ 2/10
$15.98 $16.89▲ +5.69%▲ +4.31%$17.86 (+11.76%)
Showing 10 of 13

US Market Status

Market Closed — Opens Mon (64h 22m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access